Wolmark N, Fisher B: Adjuvant chemotherapy in stage-II breast cancer: An overview of the NSABP clinical trials. Breast Cancer Res Treat 3(suppl):S19-S26, 1983.Wolmark, N., Fisher, B.: Adjuvant chemotherapy in stage II breast cancer: An overview of the NSABP clinical trials. Breast ...
Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18 kg m−2, to receive either a fasting mimicking diet (FM...
Ina was 51 years old when she was diagnosed with Stage 2 left breast cancer with nodal metastases. This was 12 years ago – around July 2012. She underwent surgery to remove the cancerous breast but refused further medical treatment – no radiation , no chemo and no tamoxifen, etc. She o...
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer PURPOSE: To determine if time to start of adjuvant chemotherapy after curative surgery influences survival in early-stage breast cancer. PATIENTS AND METHO... Sénchez,C. Jara - ...
et al. Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85). Br J Cancer 76, 545–550 (1997). https://doi.org/10.1038/bjc.1997.423 Download citation Issue Date01 August 1997 DOIhttps://doi.org/10.1038/...
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer Two hundred and eleven patients with node-positive stage II and III breast cancer were treated with eight cycles of adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt...
Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE.Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist. 2004;9(1):25-32.Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III...
Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis w... She was receiving chemotherapy for stage IV breast cancer initially thought to be metastatic only to the bones. During salvage therapy with high...
The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the effic
conferred by the combination. Our findings suggest that combination with immunomodulatory therapies is more effective if administered during the early stage of chemotherapy, before the second cycle for instance, rather than after the end of treatment. Moreover, IO combination probably improves outcome ...